Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections.

ABSTRACT: Clostridium difficile is the leading infectious cause of antibiotic-associated diarrhea and colitis. C. difficile infection (CDI) places a heavy burden on the healthcare system, with nearly half a million infections yearly and an approximate 20% recurrence risk after successful initial therapy. The high incidence has driven new research on improved prevention such as the emerging use of probiotics, intestinal microbiome manipulation during antibiotic therapies, vaccinations, and newer antibiotics that reduce the disruption of the intestinal microbiome. While the treatment of acute C. difficile is effective in most patients, it can be further optimized by adjuvant therapies that improve the initial treatment success and decrease the risk of subsequent recurrence. Finally, the high risk of r

SUBMITTER: Dieterle MG 

PROVIDER: S-EPMC6312459 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature